Meet Our Team
Management
J. Michael Redmond
President & CEO
Mr. Redmond has over 35 years commercial experience in medical device companies. Mr. Redmond held various sales and marketing positions at Abbott Laboratories, a multi-billion-dollar healthcare company. Mr. Redmond then went on to become the Director of Marketing and Business Development at KMC Systems Inc., now a leading private label developer and manufacturer of medical devices and instrumentation. Mr. Redmond helped grow the company from early stage to over $50M in revenue. KMC was sold to Elbit systems. Mr. Redmond then joined Bioject Inc as its VP of Sales and Marketing. Bioject was a medical device company specializing in unique drug delivery technologies. Mr. Redmond helped raise over $15M in capital, entered several licensing and distribution deals with major biotech and pharmaceutical companies growing the market cap of the company from under $10M to over $400M. Mr. Redmond has been CEO of Odyssey Health, Inc. since 2018.
Christine M. Farrell
Chief Financial Officer & Secretary
Christine M. Farrell joined Odyssey in April 2019 as a financial consultant serving as our Controller and Secretary and became Chief Financial Officer and Secretary in January 2021. From February 1997 to 2014, Ms. Farrell was Vice President of Finance for Bioject Medical Technologies Inc., a medical device company specializing in unique drug delivery technologies. Prior to joining Bioject, Ms. Farrell held accounting and financial management positions with Spar-Tek Industries, a manufacturer of high quality and cutting-edge technology for the plywood industry, and Action Machinery, a seller of new and used robotic machine tools and equipment. Ms. Farrell holds a B.A. degree in Accounting from the University of Washington and an M.B.A. from Willamette University in Salem, Oregon.
Greg Gironda
Chief Operating Officer
Greg Gironda has over 30 years of pharmaceutical and biotechnology experience. Greg has held various strategic planning and business development roles at companies like King Pharmaceuticals, Labopharm, EMD Serono, Neura Therapeutik, and Genentech. Greg has built commercial infrastructures and processes for various biopharma companies and has overseen the advancement of multiple pharmaceutical products from conception to commercialization.
Board of Directors
J. Michael Redmond
Chairman of the Board
Jerome H. Casey
Jerome H. Casey has been a Director since September 2019. Mr. Casey has been a leader in the life science industry for over 30 years. Mr. Casey served as a senior executive at Genzyme Corporation, a biotechnology company, from 1989 to 2011. Mr. Casey was the driver behind Genzyme’s commercial success in the diagnostics arena, building a $175 million business which Genzyme sold to Japan-based Sekisui Chemical in 2011. Mr. Casey then became the President and COO of the new entity, Sekisui Diagnostics, LLC, until the end of 2014. While President and COO, Mr. Casey established the strategic direction for the company; led the global organization, including the commercial, operations, research and development, finance, human resources, and legal functions; and achieved the annual and long-term financial objectives of the business. Since 2015, Mr. Casey has been actively involved in several life sciences ventures, both as an advisor and an investor, while serving on multiple Boards. Mr. Casey holds an M.B.A. degree in Finance and a B.A. degree in Political Science from the University of Connecticut.
Ricky W. Richardson
Ricky W. Richardson has been a Director since May 2021. Mr. Richardson has over 30 years of experience as a global operations and quality leader. He possesses strong operations and quality experience that includes change management, multi-plant operations, financial acumen, supply chain/vendor management, strategic business development, start-up planning and execution, new product introductions, and lean deployment. His most recent positions included Corporate Director of Danaher Business Systems (“DBS”). From February 2008 to July 2011, Mr. Richardson was Director of Operations for Continuous Improvement for Stryker Orthopaedics, a multi-billion dollar global manufacturer of Orthopaedics. Prior to this, Mr. Richardson held various positions at Bioject Medical Technologies, Inc., Baxter Healthcare, and Texas Instruments. From 1984 to 1987, he was a Lieutenant, Field Artillery, with the U.S. Army. He holds a B.S. degree in Engineering from the U.S. Military Academy, West Point, NY.
Scientific Advisory Board
James P. Kelly, MA, MD, FAAN, FANA
Dr. Kelly is the Executive Director of the Marcus Institute for Brain Health (MIBH) and Professor of Neurology at the University of Colorado Anschutz Medical Campus in Aurora, CO. The MIBH is a specialized treatment program funded by the Marcus Foundation to care for US military Veterans with persistent symptoms of TBI. He is also National Director of the Gary Sinise Foundation Avalon Network TBI Medical Programs for which the MIBH serves as the clinical coordinating center.
His immediate past position was Director of the National Intrepid Center of Excellence (NICoE) at Walter Reed National Military Medical Center in Bethesda, MD. As its founding Director, he led the creation of an innovative interdisciplinary team of healthcare professionals who blended high-tech diagnosis and treatment with complementary and alternative medical interventions in a holistic, integrative approach to the care of US military personnel with the complex combination of TBI and psychological conditions such as post-traumatic stress, depression and anxiety. In this role, Dr. Kelly was frequently called upon by leaders of the Military Health System in the Pentagon, the US Congress, the Department of Veterans Affairs and numerous military facilities in the continental US and abroad. He twice traveled to Afghanistan to advise and assist at military hospital programs and forward operating base medical units.